Please select the eligibility criteria that correspond to the clinical trial below.
Title: Kansas University DHA Outcome Study (KUDOS)
Brief Summary: The purpose of the study is to determine if increasing DHA intake during pregnancy can increase gestation duration and enhance infant and childhood outcomes related to visual acuity, stereoacuity, attention, and distractibility.


Options:
A: Inclusion Criteria:

* 18-22 weeks pregnant (based on last menstrual period)
* 18 - 35 years old
* Resident of Cuernavaca who intends to deliver at the IMSS General Hospital I and remain in the area for the 2 years following recruitment
* Intends to predominantly breastfeed infant until 3 months of age
* Agrees to participate with informed consent

Exclusion criteria

* High risk pregnancy: If documented in the clinical record at recruitment and will include history and prevalence of abruptio placentae, any serious bleeding episode in the current pregnancy, gestational diabetes, pregnancy induced hypertension, maternal toxoplasmosis infection during pregnancy, coagulation disorders, thrombocytopenia or chronic vascular, renal or systemic disease and drug use.
* Lipid metabolism (hyperlipidemia) and/or absorption disorders
* Regular intake of fish oil or DHA supplements during pregnancy
* Chronic use of medication for illnesses like epilepsy
B: Inclusion Criteria:

* Age: from 20 - 35 years old.
* Pregnant from 30 week to 32 week gestation.
* Singleton pregnancy with asymmetrical intrauterine growth restriction .
* Normal uterine and umbilical Doppler indices at time of recruitment.

Exclusion Criteria:

* Multiple gestations.
* Hypertensive women.
* Premature rupture of membranes.
* Abnormal Doppler indices in the form of Doppler blood flow indices \> 2 standard deviation , absent diastolic flow and lastly; reversed flow.
* Congenital fetal malformation.
* Pregnancy complicated by antepartum hemorrhage.
* Marked decrease in Amniotic fluid volume.
C: Inclusion Criteria:

* Pregnant 8-20 wks at enrollment
* single fetus
* BMI \<40

Exclusion Criteria:

* diabetes (Type I, ii, GDM)
* hypertension (primary, PIH, preeclampsia/eclampsia)
D: Inclusion Criteria:

* 18 to 35 year old pregnant women (singleton) at \<=20 weeks of gestation (calculated from the LMP by study physician).
* Willing to participate in the study and perform all measurements for self, husband and the offspring including anthropometry, dietary assessment, questionnaires and biological samples (blood and breast milk).
* Willing to provide signed and dated informed consent.

Exclusion Criteria:

* Women allergic (if aware) to any of the test products.
* Women at high risk for hemorrhagic bleeding, clotting (if aware).
* Women with high-risk pregnancies (history and prevalence of pregnancy complications, including abruptio placentae, preeclampsia, pregnancy-induced hypertension, any serious bleeding episode in the current pregnancy, and/ or physician referral); and/or diagnosed chronic degenerative disease(s) such as diagnosed heart disease, cancer, stroke or diabetes (as omega-3 could raise blood sugar and lower insulin production).
* Women consuming omega-3 supplements or having used these in 3 months preceding the intervention period.
* Reported participation in another biomedical trial 3 months before the start of the study or during the study (not to get the results of the present study contaminated).

Answer: C